click on circles to display study description...
everolimus (n=-9) vs. placebo (n=-9)
randomized controlled trial
everolimus for 2 years combined with standard endocrine therapy
placebo for 2 years combined with standard placebo
breast cancer - adjuvant
double-blind
sapanisertib plus fulvestrant (n=47) vs. fulvestrant (n=46)
randomized controlled trial
sapanasertib plus fulvestrant
sapanisertib: 4 mg orally daily / fulvestrant: 500 mg intramuscularly every 28 days
fulvestrant
fulvestrant: 500 mg intramuscularly every 28 days
la/mBC - HR-positive - 2nd line (L2)
open label
50 study sites in the United States and Spain
P2 / PFS at 2-sided at 0.1 / No formal interim analysis is planned.
It seems that adding sapatinertib daily or weekly did not improve significantly PFS
sapanisertib plus fulvestrant (n=48) vs. fulvestrant (n=46)
randomized controlled trial
sapinasertib plus fulvestrant
sapanisertib: 30 mg orally weekly / fulvestrant: 500 mg intramuscularly every 28 days
fulvestrant
fulvestrant: 500 mg intramuscularly every 28 days
la/mBC - HR-positive - 2nd line (L2)
open label
50 study sites in the United States and Spain
P2 / PFS at 2-sided at 0.1 / No formal interim analysis is planned.
It seems that adding sapatinertib daily or weekly did not improve significantly PFS
powered by vis.js Network